Jefferies | Rovi Laboratories (ROVI), ahead of its CMD (9am UKT), has announced a revenue forecast for FY30E of 1.5-1.8 times FY24 levels, a midpoint of €1.261 billion (up 10% versus estimated JEF €1.144 billion). This growth is driven by the forecast of a two-fold increase in CDMO revenues in 24, to around €700 million in 2030E (up 60% compared to €429 million in 2005). Including the additional €250 million…
Bankinter: In a Significant Event, Rovi announced that it expects its EBITDA 2024 to be lower, in a range between 10% and 15%, than expected by the market. The company will publish its annual results on 25 February. It maintains its forecasts for the current financial year 2025 (Sales down 10%/0%). Analysis team’s opinion: Negative news. Consensus market estimates indicate sales 2024 of €787m (down 5% year-on-year) which is in…
Bankinter | Laboratorios Rovi (ROVI) is negotiating with the CVC fund the sale of its third-party manufacturing business. The valuation of 100% of this business could exceed €3,000 million. Antin, Cinven, KKR and Permira have dropped out of the bidding. Opinion of Bankinter’s analysis team: Positive news that opens the possibility for Rovi to value its assets, the first glimpses of which we saw in March. Sales of the manufacturing…